Happy Friday, folks. Here is my BioBusiness update for the week with the top ten headlines I found.
My BioBusiness updates focus on fund raises, mergers, collaborations, IPOs, and key appointments across biotech, pharma and medical devices.
Let me know if I’ve missed any important pieces of news.
➡ Johnson Matthey sells off medtech metal manufacturing unit to Montagu in $700m private equity deal
➡ Investors fund Prometheus team’s ‘unfinished business’ with $400m for new inflammatory biotech Mirador Therapeutics
➡ Third Rock, Novo Holdings-backed Clasp Therapeutics hooks $150m series A for next-gen cancer treatments
➡ Engrail Therapeutics closes $157M series B, fuelled by investors’ renewed interest in neuropsychiatry
➡ Skin care company Galderma’s shares soared on Friday after the maker of cosmetic fillers and medical creams made its stock market debut in Switzerland.
➡ Capstan Therapeutics secures $175m oversubscribed Series B with backing from J&J, Bayer and Bristol Myers Squibb
➡ CHARM Therapeutics announces foundation of Scientific Advisory Board, with key experience spanning 3D deep learning and protein structure prediction, drug discovery and oncology.
➡ Basel-headquartered Roche has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
➡ British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for $2bn upfront.
➡ Titan Medical to merge with imaging firm Conavi, ending strategic review, focusing on cardiovascular imaging technology.
Have a great weekend.
#biotech
#medicaldevices
#pharma